Testing a new antibody treatment for early memory loss and mild dementia

This study is testing a medication called Lecanumab, which is a type of antibody designed to target and remove harmful protein deposits (amyloid) that build up in the brains of people with Alzheimer's disease. Researchers believe that by clearing these toxic deposits, the medication may help slow memory loss and thinking problems in people with early-stage disease. The trial will compare people who receive Lecanumab plus standard dementia medications against those who receive standard treatment alone.

Large global studies have shown that this medication can slow cognitive decline in early Alzheimer's disease, but doctors and researchers don't fully understand exactly how it works in the brain. This trial aims to investigate whether the treatment's benefits come from restoring the brain's ability to form new connections between nerve cells—a process critical for memory and thinking.